The Drug Enforcement Administration (DEA) has announced a significant delay in its decision on marijuana rescheduling, pushing the timeline beyond the upcoming presidential election. According to a recent Forbes report, the DEA has scheduled a hearing for December 2 to discuss the Biden administration’s proposal to reclassify marijuana under federal drug laws. This move effectively
The Drug Enforcement Administration (DEA) has announced a significant delay in its decision on marijuana rescheduling, pushing the timeline beyond the upcoming presidential election. According to a recent Forbes report, the DEA has scheduled a hearing for December 2 to discuss the Biden administration’s proposal to reclassify marijuana under federal drug laws.
This move effectively postpones any final ruling until after November’s election, potentially making cannabis policy a key issue for voters. The delay comes amid growing public support for marijuana reform and increasing pressure from advocacy groups and lawmakers.
The rescheduling decision could have far-reaching implications for the cannabis industry, medical research, and criminal justice reform. As the debate continues, stakeholders on all sides are closely watching how this delay might influence both the election and the future of marijuana policy in the United States.